SCHEDULE: Janus Henderson Discloses 11.5% Stake in Vaxcyte

Janus Henderson Group plc has reported beneficial ownership of 16,575,875 shares, representing 11.5% of Vaxcyte, Inc.'s common stock as of March 31, 2026.

Summary

• Janus Henderson Group plc, through its various asset management subsidiaries, has filed a Schedule 13G indicating beneficial ownership of 16,575,875 shares of Vaxcyte, Inc. common stock.
• This holding represents 11.5% of the total class of securities.
• The filing is an amendment (Amendment No. 9) and the event date requiring the filing is March 31, 2026.
• Janus Henderson Group plc is the ultimate parent of several SEC-registered investment advisers and their foreign equivalents, which collectively manage client assets.
• These asset managers may be deemed beneficial owners due to their investment and/or voting discretion over client portfolios.
• However, Janus Henderson Group plc disclaims beneficial ownership of dividends and proceeds from the sale of these securities, as these rights belong to the client portfolios.
• None of the individual Managed Portfolios own more than five percent of Vaxcyte, Inc.'s common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it indicates significant institutional interest and investment in Vaxcyte, Inc. by a major asset manager, but it is a routine disclosure and not an operational update.

Positives

• Significant institutional ownership by Janus Henderson Group plc, indicating confidence from a major asset manager.
• The 11.5% stake suggests a substantial investment in Vaxcyte, Inc.

Negatives

• The filing is a routine disclosure of beneficial ownership and does not inherently contain negative financial or operational information about Vaxcyte, Inc.

Risks

• The filing does not explicitly mention any risks related to Vaxcyte, Inc.'s operations or financial health.

Future Outlook

The filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Vaxcyte, Inc.'s future performance.

Management Comments

• Janus Henderson Group plc, through its Asset Managers, may be deemed beneficial owners due to exercise of investment and/or voting discretion.
• The Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.

Industry Context

StockSavvy.ai notes that significant institutional filings like this Schedule 13G from a major asset manager such as Janus Henderson Group plc often signal sustained investor interest in the biotechnology sector, particularly for companies with promising drug development pipelines.

Stakeholder Impact

• Shareholders: The significant stake by Janus Henderson Group plc may be viewed positively, potentially indicating stability and institutional support for Vaxcyte, Inc.

Next Steps

• Janus Henderson Group plc will continue to hold its stake in Vaxcyte, Inc. as per its investment mandates.
• Further amendments to the Schedule 13G may be required if there are material changes in beneficial ownership.

Key Dates

Keywords

Vaxcyte, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Biotechnology